(Q36905233)

17 August 2017

1 reference

title

Improving patient management in metastatic non-small cell lung cancer (English)

1 reference

17 August 2017

Johan Vansteenkiste

1

1 reference

17 August 2017

publication date

1 August 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

57 Suppl 2

1 reference

17 August 2017

page(s)

S12-7

1 reference

Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2807%2970422-1

7 January 2021

10.1016/S0169-5002(07)70422-1

Identifiers

DOI

1 reference

17 August 2017

1 reference